AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $41.45.

ANAB has been the topic of a number of research reports. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. BTIG Research cut shares of AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. HC Wainwright cut shares of AnaptysBio from a "buy" rating to a "neutral" rating and lowered their target price for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Wells Fargo & Company lowered their target price on shares of AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a report on Thursday, December 12th. Finally, JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $66.00 to $36.00 and set an "overweight" rating on the stock in a report on Thursday, December 19th.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc bought 65,184 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now owns 7,860,180 shares of the company's stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently modified their holdings of ANAB. The Manufacturers Life Insurance Company raised its stake in AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company's stock worth $634,000 after buying an additional 8,418 shares in the last quarter. Algert Global LLC increased its stake in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of AnaptysBio during the third quarter valued at approximately $405,000. Duncan Williams Asset Management LLC bought a new position in shares of AnaptysBio during the third quarter valued at approximately $282,000. Finally, nVerses Capital LLC increased its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter.

AnaptysBio Trading Down 7.1 %

Shares of NASDAQ:ANAB traded down $1.27 during mid-day trading on Friday, reaching $16.66. The company had a trading volume of 561,657 shares, compared to its average volume of 676,646. The firm has a market cap of $506.96 million and a price-to-earnings ratio of -2.74. The company's 50-day moving average price is $17.38 and its 200-day moving average price is $27.01. AnaptysBio has a one year low of $12.51 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, research analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.